THE IMPACT OF WATER-SOLUBLE C60 FULLERENES ON THE DEVELOPMENT OF ACUTE COLITIS IN RATS
DOI: http://dx.doi.org/10.30970/sbi.1101.509
Abstract
Anti-inflammatory drugs are traditionally applied for the treatment of acute colitis of various etiologies. However, they have several disadvantages due to intestinal and extraintestinal complications and lowefficiency. Therefore, a search for new agents which would be effective at colonic inflammation is relevant. Potential anti-inflammatory and protective properties of the water-soluble C60 fullerenes on rat acute ulcerative colitis model were assessed. Acute colitis was induced by rectal administration of 0.5 ml of 10% acetic acid solution. C60 fullerenes (0.5 mg/kg body weight) in the stable aqueous solution were administered intraperitoneally or rectally at 24 and 48 h after the colitis induction. Animals were euthanized at 24 h after the last administration. State of the colon was evaluated macroscopically by 10-grade scale, and the colon epithelial barrier permeability was assessed for diurnal phenol red excretion. The levels of serum blood transaminases, creatinine and urea were also measured for liver and kidney state assessment. Colonic lesions were reduced in some animals (3 of total number of 6) by C60 fullerenes administered intraperitoneally. Moreover, mucosal damage was significantly weaker in all animals under C60 fullerenes rectal administration (3 grades vs 5). C60 fullerenes applied by both methods partially corrected local and systemic changes: colon mucosa epithelial barrier and kidney and liver functions were restored. Thus, C60 fullerenes correct local and systemic consequences of the acute colitis. The protective effects of C60 fullerenes are more pronounced at topical administration compared with the intraperitoneal one.
Keywords
Full Text:
PDF (Українська)References
1. Ambruzs J.M., Walker P.D., Larsen C.P. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin. J. Am. Soc. Nephrol, 2014; 9(2): 265-270. | |
| |
2. Bamba S., Tsujikawa T., Sasaki M. et al. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol, 2011; 2011: 194324. | |
| |
3. Boyko T.I. Extraintestinal manifestations of inflammatory bowel disease. News of Medicine and Pharmacy, 2010; 18(341). (In Russian) | |
| |
4. Cottone M., Renna S., Modesto I., Orlando A. Is 5-ASA still the treatment of choice for ulcerative colitis? Curr. Drug Targets, 2011; 12(10): 1396-1405. | |
| |
5. Dresselhaus M.S., Dresselhaus G., Eklund P.C. Science of Fullerenes and Carbon Nanotubes: Their Properties and Applications. New York: Academic Press, 1996, 985 p. | |
| |
6. Feuerstein J.D., Cheifetz A.S. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo. Clin. Proc, 2014; 89(11): 1553-1563. | |
| |
7. Fitzpatrick L.R., Bostwick J.S., Renzetti M. Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat. Agents Actions, 1990; 30: 393-403. | |
| |
8. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol, 2006; 72(11): 1493-1505. | |
| |
9. Hada M., Omura K., Hirano Y., Watanabe G. Changes in bowel mucosal permeability and wound healing after neoadjuvant chemotherapy. Oncology Letters, 2010; 1: 161-165. | |
| |
10. Halenova T.I., Vareniuk I.M., Roslova N.M. et al. Hepatoprotective effect of orally applied water-soluble pristine C60 fullerene against CCl4-induced acute liver injury in rats. RSC Adv, 2016; 6(102): 100046-100055. | |
| |
11. Kaser A., Zeissig S., Blumberg R. Inflammatory Bowel Disease. Annu Immunol, 2010; 28: 573-621. | |
| |
12. Kolosnjaj J., Szwarc H., Moussa F. Toxicity studies of fullerenes and derivatives. Adv. Exp. Med. Biol, 2007; 620: 168-180. | |
| |
13. Lakatos P. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol, 2006; 12(38): 6102-6108. | |
| |
14. Levine J.S., Burakoff R. Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastroenterol. Hepatol. (N Y), 2011; 7(4): 235-241. | |
| |
15. Low D., Nguyen D.D., Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. Drug Des. Devel. Ther, 2013; 7: 1341-1357. | |
| |
16. Matsuda S., Matsui S., Shimizu Y., Matsuda T. Genotoxicity of colloidal fullerene С60. Environ. Sci. Technol, 2011; 1: 4133-8. | |
| |
17. Moura F.A., de Andrade K.Q., Farias dos Santos J.C. et. al. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol, 2015; 6: 617-639. | |
| |
18. Nozdrenko D., Prylutskyy Yu., Ritter U., Scharff P. Protective effect of water-soluble pristine C60 fullerene in ischemia-reperfusion injury of skeletal muscle. Int. J. Physiol. Pathophysiol, 2014; 5(2): 97-110. | |
| |
19. Piotrovskyy L.B., Kiselyov O.I. Fullerenes in biology (on the way to nanomedicine). St. Petersbourg: Rostoc, 2006. 336 p. (In Russian) | |
| |
20. Prylutska S., Bilyy R., Overchuk M. et al. Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J. Biomed. Nanotechnol, 2012; 8: 522-527. | |
| |
21. Prylutska S.V., Burlaka A.P., Klymenko P.P. et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol, 2011; 2(1): 105-110. | |
| |
22. Prylutska S.V., Grynyuk I.I., Grebinyk S.M. et al. Comparative study of biological action of fullerenes C60 and carbon nanotubes in thymus cells. Mat-wiss. u. Werkstofftech, 2009; 40(4): 238-241. | |
| |
23. Prylutska S.V., Grynyuk I.I., Matyshevska O.P. et al. Anti-oxidant properties of C60 fullerenes in vitro. Fullerenes, Nanotubes, Carbon Nanostruct, 2008; 16(5-6): 698-705. | |
| |
24. Prylutska S.V., Matyshevska O.P., Prylutskyy Yu.I. et al. Biological effects of C60 fullerenes in vitro and in a model system. Mol. Cryst. Liq. Cryst, 2007; 468(1): 265-274. | |
| |
25. Prylutskyy Yu. I., Petrenko V. I., Ivankov O. I. et al. On the origin of C60 fullerene solubility in aqueous solution. Langmuir, 2014; 30(14): 3967-3970. | |
| |
26. Ranganathan P., Jayakumar C., Manicassamy S., Ramesh G. CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am. J. Physiol. Renal. Physiol, 2013; 305: F1422-F1427. | |
| |
27. Ritter U., Prylutskyy Yu. I., Evstigneev M. P. et al. Structural features of highly stable reproducible C60 fullerene aqueous colloid solution probed by various techniques. Fullerenes, Nanotubes, Carbon Nanostruct, 2015; 23(6): 530-534. | |
| |
28. Sehirli А., Tathdede E., Yaksel M. et al. Protective effects of alfa-lipoic acid against oxidative injury in TNBS-induced colitis. Erciyes Medical Journal, 2009; 31(1): 15-26. | |
| |
29. Sergijenko V.I., Bondareva I.B. Mathematical statistics in сlinical trials. Moscow: GEOTAR Medicine, 2006. 304 p. (In Russian) | |
| |
30. Sumner S.C.J., Snyder R.W., Wingard C. et al. Distribution and biomarkers of carbon-14-labeled fullerene C60 ([14C(U)]C60) in female rats and mice for up to 30 days after intravenous exposure. J. Appl. Toxicol, 2015; 35: 1452-1464. | |
| |
31. Takahashi M., Kato H., Doi Y. et. al. Sub-acute oral toxicity study with fullerene C60 in rats. J. Toxicol. Sci, 2012; 37(2): 353-361. | |
| |
32. Tolkachov M., Sokolova V., Korolovych V. et al. Study of biocompatibility effect of nanocarbon particles on various cell types in vitro. Mat-wiss. u. Werkstofftech, 2016; 47(2-3): 216-221. | |
| |
33. Vezza T., Rodríguez-Nogales A., Algieri F. et al. Flavonoids in Inflammatory Bowel Disease: A Review. Nutrients, 2016; 8(4): 211. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2017 Studia biologica